Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521), through its subsidiary Shanghai Huaota Biopharmaceutical Co., Ltd., has announced the first subject dosing in a clinical study for its potential first-in-class drug, HB0056, in New Zealand. This marks a significant step forward in the development of this innovative therapy.
HB0056: A Bispecific Antibody Targeting TSLP and IL-11 Pathways
HB0056 is a bispecific antibody (BsAb) that targets thymic stromal lymphopoietin (TSLP) and interleukin 11 (IL-11), two cytokines that play a role in inducing Th2 response, airway inflammation, and the pathogenesis of asthma through various mechanisms. By simultaneously blocking both the TSLP and IL-11 pathways, HB0056 is intended for the treatment of patients with airway remodeling and fibrosis resulting from persistent inflammation. This dual-targeting approach could offer a novel treatment option for asthma patients.
Global Context and Competitive Landscape
Currently, no similar product to HB0056 has been approved worldwide. However, Tezspire (tezepelumab), a TSLP monoclonal antibody co-developed by AstraZeneca and Amgen, has been registered in the US and European Union as an adjunctive maintenance therapy for severe asthma in children and adult patients aged 12 years and above. The development of HB0056 positions Zhejiang Huahai Pharmaceutical at the forefront of innovative asthma treatments.-Fineline Info & Tech
Leave a Reply